Albuterol via metered-dose inhaler in children: Lower doses are effective, and higher doses are safe

Muchão, Fábio Pereira; Souza, Juliana Miguita e; Torres, Hélida Conceição Cavalcante; Lalibera, I. B.; Souza, Andréa Vieira de; Rodrigues, Joaquim Carlos; Schvartsman, Cláudio; Filho, Luiz Vicente Ribeiro Ferreira da Silva

doi:10.1002/ppul.23469

Cited by 12 publications

(16 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, under the force of concentration gradients, AS release followed the same kinetic law. Since AS is a-first-line agent for treatment and prevention of bronchospasm in patients with asthma and chronic obstructive pulmonary disease,62,63 the pharmacodynamic properties of AS-BSA-NPs should confer benefits to these patients via the targeted and rapid release of a bronchodilator after NPs arrive at the distal bronchi. Large hollowed NP aggregates have many merits, including prolonging drug release, enhanced drug utilization, and alleviation of administration frequency, giving rise to improved patient compliance 64,65.…”

Section: Discussionmentioning

confidence: 99%

Fenretinide inhibits macrophage inflammatory mediators and controls hypertension in spontaneously hypertensive rats via the peroxisome proliferator-activated receptor gamma pathway

Lin¹,

Lee²,

Zhang³

et al. 2016

DDDT

View full text Add to dashboard Cite

Fenretinide is a novel anticancer agent reported to exhibit anti-invasive and antimetastatic activities. It has also been shown to improve obesity and diabetes, although the effects of fenretinide on hypertension are still unknown, and the detailed mechanisms remain unclear. In this study, we have shown that treatment with lipopolysaccharide (LPS) decreased the expression of peroxisome proliferator-activated receptor γ (PPARγ) in RAW264.7 macrophages, and pretreatment with fenretinide reversed the effect of LPS on PPARγ expression. In addition, LPS-induced pro-inflammatory cytokine production, including tumor necrosis factor-α, interleukin 6, and monocyte chemoattractant protein 1 were dose-dependently reversed by fenretinide, and the effects of fenretinide on LPS-induced pro-inflammatory cytokine production were blocked by treatment with PPARγ antagonist. Moreover, fenretinide decreased LPS-induced inducible nitric oxide synthase expression and nitrogen oxide production. These effects were blocked by the pretreatment with PPARγ antagonist in a dose-dependent manner, indicating fenretinide activated PPARγ to exert anti-inflammation activity. In view of the role of inflammation in hypertension and the anti-inflammatory action of fenretinide, we found that administration of fenretinide in spontaneously hypertensive rats significantly decreased blood pressure. Taken together, these results indicate that fenretinide might be a potent antihypertensive agent that works by suppressing inflammation via activating PPARγ.

show abstract

Section: Discussionmentioning

confidence: 99%

Fenretinide inhibits macrophage inflammatory mediators and controls hypertension in spontaneously hypertensive rats via the peroxisome proliferator-activated receptor gamma pathway

Lin¹,

Lee²,

Zhang³

et al. 2016

DDDT

View full text Add to dashboard Cite

show abstract

“…Although our intervention increased MDI dosing, studies have shown conflicting results about whether there is clinical benefit to using a larger dose of albuterol. [15][16][17] A 2016 randomized trial compared large-dose albuterol to small dose in children with moderate to severe asthma in the ED and found no significant differences in LOS, admission rate, and safety profile. 15 Another study comparing a single, large dose (6-10 puffs) of albuterol to small dose (2 puffs) in children with mild acute asthma showed a non-significant larger improvement in forced expiratory volume in 1 second for the large-dose group.…”

Section: Discussionmentioning

confidence: 99%

A Report of an Asthma Pathway Leading to Improved Resource Use

Nian¹,

Orr²,

Schroeder³

2018

The Journal of Pediatric Pharmacology and Therapeutics

View full text Add to dashboard Cite

show abstract

“…Consequently, under the force of concentration gradients, AS release followed the same kinetic law. Since AS is a-first-line agent for treatment and prevention of bronchospasm in patients with asthma and chronic obstructive pulmonary disease, 62 , 63 the pharmacodynamic properties of AS-BSA-NPs should confer benefits to these patients via the targeted and rapid release of a bronchodilator after NPs arrive at the distal bronchi. Large hollowed NP aggregates have many merits, including prolonging drug release, enhanced drug utilization, and alleviation of administration frequency, giving rise to improved patient compliance.…”

Section: Discussionmentioning

confidence: 99%

Combined computational and experimental studies of molecular interactions of albuterol sulfate with bovine serum albumin for pulmonary drug nanoparticles

Lin

Cui

Wang

et al. 2016

DDDT

View full text Add to dashboard Cite

Albumin-based nanoparticles (NPs) are a promising technology for developing drug-carrier systems, with improved deposition and retention profiles in lungs. Improved understanding of these drug–carrier interactions could lead to better drug-delivery systems. The present study combines computational and experimental methods to gain insights into the mechanism of binding of albuterol sulfate (AS) to bovine serum albumin (BSA) on the molecular level. Molecular dynamics simulation and surface plasmon resonance spectroscopy were used to determine that there are two binding sites on BSA for AS: the first of which is a high-affinity site corresponding to AS1 and the second of which appears to represent the integrated functions of several low-affinity sites corresponding to AS2, AS3, and AS8. AS1 was the strongest binding site, established via electrostatic interaction with Glu243 and Asp255 residues in a hydrophobic pocket. Hydrogen bonds and salt bridges played a main role in the critical binding of AS1 to BSA, and water bridges served a supporting role. Based upon the interaction mechanism, BSA NPs loaded with AS were prepared, and their drug-loading efficiency, morphology, and -release profiles were evaluated. Successful clinical development of AS-BSA-NPs may improve therapy and prevention of bronchospasm in patients with reversible obstructive airway disease, and thus provide a solid basis for expanding the role of NPs in the design of new drug-delivery systems.

show abstract

Albuterol via metered-dose inhaler in children: Lower doses are effective, and higher doses are safe

Abstract: Higher albuterol dosage regimens did not result in lower admission rate or shorter length of stay in the ER, but showed similar safety profile for children with moderate to severe acute asthma. Pediatr Pulmonol. 2016;51:1122-1130. © 2016 Wiley Periodicals, Inc.

Cited by 12 publications

References 27 publications

Fenretinide inhibits macrophage inflammatory mediators and controls hypertension in spontaneously hypertensive rats via the peroxisome proliferator-activated receptor gamma pathway

Fenretinide inhibits macrophage inflammatory mediators and controls hypertension in spontaneously hypertensive rats via the peroxisome proliferator-activated receptor gamma pathway

A Report of an Asthma Pathway Leading to Improved Resource Use

Combined computational and experimental studies of molecular interactions of albuterol sulfate with bovine serum albumin for pulmonary drug nanoparticles

Contact Info

Product

Resources

About